VERTEX PHARMACEUTICALS INC MA
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
VRTX$550.87+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets -
(in millions, except share data)(unaudited)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $9,158.0 | $10,369.1 |
| Marketable securities | 1,013.3 | 849.2 |
| Accounts receivable, net | 1,793.2 | 1,563.4 |
| Inventories | 813.1 | 738.8 |
| Prepaid expenses and other current assets | 511.1 | 623.7 |
| Total current assets | 13,288.7 | 14,144.2 |
| Property and equipment, net | 1,172.8 | 1,159.3 |
| Goodwill | 1,088.0 | 1,088.0 |
| Other intangible assets, net | 834.9 | 839.9 |
| Deferred tax assets | 1,963.0 | 1,812.1 |
| Operating lease assets | 312.9 | 293.6 |
| Long-term marketable securities | 4,381.4 | 2,497.8 |
| Other assets | 875.7 | 895.3 |
| Total assets | $23,917.4 | $22,730.2 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $351.4 | $364.9 |
| Accrued expenses | 2,795.9 | 2,655.3 |
| Other current liabilities | 648.6 | 527.2 |
| Total current liabilities | 3,795.9 | 3,547.4 |
| Long-term finance lease liabilities | 361.5 | 376.1 |
| Long-term operating lease liabilities | 359.8 | 348.6 |
| Other long-term liabilities | 853.6 | 877.7 |
| Total liabilities | 5,370.8 | 5,149.8 |
| Commitments and contingencies | — | — |
| Shareholders’ equity: | ||
| Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding | — | — |
| Common stock, $0.01 par value; 500,000,000 shares authorized, 258,296,249 and 257,695,221 shares issued and outstanding, respectively | 2.6 | 2.6 |
| Additional paid-in capital | 7,284.7 | 7,449.7 |
| Accumulated other comprehensive income (loss) | 17.3 | (14.3) |
| Retained earnings | 11,242.0 | 10,142.4 |
| Total shareholders’ equity | 18,546.6 | 17,580.4 |
| Total liabilities and shareholders’ equity | $23,917.4 | $22,730.2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.